PolyPeptide Group AG Logo

PolyPeptide Group AG

A CDMO specializing in peptide and oligonucleotide-based active pharmaceutical ingredients.

PPGN | SW

Overview

Corporate Details

ISIN(s):
CH1110760852
LEI:
5067007JCKTPOX4G9758
Country:
Switzerland
Address:
Neuhofstrasse 24, 6340 Baar

Description

PolyPeptide Group AG is a Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company serves the pharmaceutical and biotech sectors by providing a comprehensive range of services that cover all stages of product development, from pre-clinical to commercial manufacturing. Its offerings include both proprietary (custom) and generic GMP-grade peptides. PolyPeptide focuses on innovation in peptide synthesis and manufacturing processes to support the development of therapies for patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-12 07:00
PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet G…
English 9.9 KB
2025-12-12 01:00
PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet G…
English 8.2 KB
2025-09-22 07:00
PolyPeptide Group achieves significant milestone in Malmo expansion project
English 10.6 KB
2025-09-22 02:00
PolyPeptide Group achieves significant milestone in Malmö expansion project
English 8.5 KB
2025-08-12 06:55
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian …
English 31.7 KB
2025-08-12 02:00
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian …
English 28.4 KB
2025-08-12 02:00
PolyPeptide wächst im ersten Halbjahr 2025 um 24%, mit einer erfolgreichen Anla…
German 32.6 KB
2025-05-23 07:00
PolyPeptide announces expansion of existing credit facilities
English 7.8 KB
2025-05-23 02:00
PolyPeptide announces expansion of existing credit facilities
English 6.0 KB
2025-05-23 02:00
PolyPeptide gibt Ausweitung des bestehenden Kreditrahmens bekannt
German 7.0 KB
2025-04-09 18:34
PolyPeptide announces results of the annual General Meeting 2025
English 9.3 KB
2025-03-19 07:00
PolyPeptide publishes invitation to the annual General Meeting 2025
English 8.8 KB
2025-03-18 07:00
PolyPeptide publishes invitation to the annual General Meeting 2025
English 8.8 KB
2025-03-18 01:00
PolyPeptide publishes invitation to the annual General Meeting 2025
English 7.1 KB
2025-03-18 01:00
PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025
German 8.0 KB

Automate Your Workflow. Get a real-time feed of all PolyPeptide Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PolyPeptide Group AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PolyPeptide Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-09 N/A Non-Executive member Buy None 75,000.00 CHF
2025-04-09 N/A Non-Executive member Buy None 72,000.00 CHF
2025-04-09 N/A Non-Executive member Buy None 50,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 75,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 72,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 50,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 35,000.00 CHF
2023-11-10 N/A Executive member Buy None 51,250.00 CHF
2023-10-11 N/A Executive member Buy None 2,876,348.62 CHF
2023-10-10 N/A Executive member Buy None 371,202.96 CHF

Peer Companies

Aldeyra Therapeutics, Inc. Logo
Develops medications for immune-mediated ocular and systemic diseases.
United States of America
ALDX
Alector, Inc. Logo
Clinical-stage biotech using immuno-neurology to treat neurodegenerative diseases.
United States of America
ALEC
ALK-Abelló Logo
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
Denmark
ALK
Alkaloid AD Logo
Manufactures generic pharmaceuticals, cosmetics, and chemical products.
North Macedonia
ALK
Alkermes plc. Logo
Develops and commercializes medicines for central nervous system (CNS) diseases.
United States of America
ALKS
Allarity Therapeutics, Inc. Logo
A clinical-stage biopharma using diagnostics to develop targeted cancer therapies.
United States of America
ALLR
ALLERGY THERAPEUTICS PLC Logo
Immunology company developing aluminum-free vaccines and therapies for allergies.
United Kingdom
AGY
Alligator Bioscience Logo
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Sweden
ATORX
Allogene Therapeutics, Inc. Logo
Develops off-the-shelf allogeneic CAR T therapies for cancer and autoimmune diseases.
United States of America
ALLO
Almirall S.A. Logo
Global biopharmaceutical company specializing in medical dermatology and skin health.
Spain
ALM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.